Each of these inhibitors significantly suppressed the promoting effect of TGF-β1/H2O2/HOCl on invasive migration and extravasation of HepG2 cells (Figure S3), suggesting that the sustained activation of these pathways was indeed required for TGF-β1/H2O2/HOCl to induce higher invasive capacity of HCC cells. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.